John W.M. Martens

This paper develops a microfluidic platform using insulator-based dielectrophoresis to isolate breast cancer cells from blood with high recovery and purity.

The paper introduces MeD-seq, a method to profile circulating tumor DNA by analyzing DNA methylation and copy number changes, showing its effectiveness in detecting cancer-specific signals in plasma samples.

This study identifies ROPN1 as a target for TCR-engineered T-cells effective against TNBC in preclinical models and demonstrates their safety and efficacy.

The paper identifies cis-regulatory mutations in cancer that disrupt gene regulatory programs by affecting both transcriptional and post-transcriptional regulation.

This study shows that SPEN is essential for Xist upregulation during X chromosome inactivation initiation in female mouse ESCs by silencing Tsix.

This paper validates MeD-seq for cfDNA methylation profiling in cancer patients, showing distinct pre-surgical methylation patterns compared to healthy donors.

SHARC rapidly identifies somatic genomic structural variations from nanopore sequencing for blood-based cancer monitoring, detecting ten SVs per sample and enabling treatment response tracking in metastatic prostate cancer.

Dr. Disco identifies fusion transcripts and genomic breakpoints using non poly(A)-enriched RNA-seq data, revealing transcribed rearrangements and their expression effects in cancer samples.

The paper introduces DPHL, a pan-human protein mass spectrometry library built using DIA and PRM, and demonstrates its utility in identifying differentially expressed proteins in prostate cancer and DLBCL.